Abstract
Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
Keywords: Bladder cancer, genito-urinary cancers, molecular pathology, personalized therapy, precision oncology, targeted therapy.
Current Drug Targets
Title:Bladder Cancer: Molecular Determinants of Personalized Therapy
Volume: 16 Issue: 2
Author(s): Antonio Lopez-Beltran, Matteo Santoni, Francesco Massari, Chiara Ciccarese, Giampaolo Tortora, Liang Cheng, Holger Moch, Marina Scarpelli, Carlos Reymundo and Rodolfo Montironi
Affiliation:
Keywords: Bladder cancer, genito-urinary cancers, molecular pathology, personalized therapy, precision oncology, targeted therapy.
Abstract: Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
Export Options
About this article
Cite this article as:
Lopez-Beltran Antonio, Santoni Matteo, Massari Francesco, Ciccarese Chiara, Tortora Giampaolo, Cheng Liang, Moch Holger, Scarpelli Marina, Reymundo Carlos and Montironi Rodolfo, Bladder Cancer: Molecular Determinants of Personalized Therapy, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666150204115756
DOI https://dx.doi.org/10.2174/1389450116666150204115756 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Insights on Antimicrobial Resistance, Biofilms and the Use of Phytochemicals as New Antimicrobial Agents
Current Medicinal Chemistry Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Phosphorothioate-Stimulated Uptake of siRNA by Mammalian Cells: A Novel Route for Delivery
Current Topics in Medicinal Chemistry Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Structure and Regulation of the Drug-Metabolizing Enzymes Arylamine N-acetyltransferases
Current Medicinal Chemistry Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma
Current Topics in Medicinal Chemistry 3,7-Bis(dialkylamino)phenothiazin-5-ium Derivatives: Biomedical Applications and Biological Activity
Current Drug Targets The Alleviating Effect of Herniarin Against Ionizing Radiation-Induced Genotoxicity and Cytotoxicity in Human Peripheral Blood Lymphocytes
Current Radiopharmaceuticals Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry